Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

NCT07401992 on ClinicalTrials.gov · last registry update 2026-02-11

Recruiting now, toward 62 participants. Due to report 28 February 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Effect of GLP-1 Receptor Agonists on SCD-1 Activity. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Sponsor type: Other
Enrollment: 62
Started: 2026-01-15
Primary completion: 2027-02-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Effect of GLP-1 Receptor Agonists on SCD-1 Activity

Conditions studied

Psoriasis (PsO) · Obesity & Overweight · Diabetes Mellitus - Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.